EnteroBiotix secures £19M to support IBS microbiome clinical trial

Glasgow-based
life sciences company EnteroBiotix has secured £19 million in funding to
support the advancement of its microbiome-based therapies, including a large-scale clinical trial targeting irritable bowel syndrome (IBS). The round
was led by Thairm Bio and the Scottish National Investment Bank, with
participation from existing investors. The company has raised more than £65
million to date.

Founded
in 2017 by Dr James McIlroy, EnteroBiotix develops microbiome-based therapeutics
designed to address underlying disease biology.

The
newly raised capital will primarily support a Phase 2b clinical trial of
EBX-102-02, the company’s lead candidate for IBS. The study, involving
approximately 300 patients, is already underway, with topline efficacy data
expected in the second half of 2027.

IBS
affects a significant proportion of the global population and represents a
substantial unmet medical need. EnteroBiotix’s approach differs from
conventional probiotics by aiming to restore the microbiome more
comprehensively, with the goal of improving patient outcomes at scale.

Our
clinical data indicates that EBX-102-02 has the potential to deliver meaningful
outcomes for patients with IBS. Our goal is to address the underlying causes of
disease and improve standards of care in gastrointestinal health,

said Dr
James McIlroy, founder of EnteroBiotix.

The
company has established a number of strategic partnerships and research
collaborations, including with Imperial College London, as it continues to
advance its development programmes and expand its presence in the global
biopharmaceutical sector.

The
funding will also be used to advance EnteroBiotix’s broader clinical pipeline,
scale manufacturing capabilities, and support ongoing research and development
efforts.